Floatz logo

Temsirolimus

Adult Diffuse Astrocytoma

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Adult Diffuse Astrocytoma cohort.

Asset / SponsorPhaseRating
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Carboplatin
Novartis Pharmaceuticals
Phase 2B
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2B
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC

View all 20 →

Same molecule, other indications

Temsirolimus is also rated in:

gliosarcomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult glioblastomaDormant
BBB
Indicative ·
74 / 100
View asset →
giant cell glioblastomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →